HBsAg blood screening and diagnosis: Performance evaluation of the ARCHITECT HBsAg qualitative and ARCHITECT HBsAg qualitative confirmatory assays

Diagnostic Microbiology and Infectious Disease

Volumn 70, Issue 4, 2011, Pages 479-485

  Popp, Christian ^a   Krams, Doris ^a   Beckert, Christian ^a   Buenning, Carsten ^a   Queirós, Lucinda ^b   Piro, Loredana ^c   Luciani, Marina ^c   Roebbecke, Markus ^a   Kapprell, Hans Peter ^a  

^a ABBOTT GMBH AND CO KG   (Germany)

^b Instituto Português do Sangue   (Portugal)

^c POLICLINICO UMBERTO I   (Italy)

Author keywords

ARCHITECT HBsAg Qualitative assay; ARCHITECT HBsAg Qualitative Confirmatory assay; HBsAg blood screening

Indexed keywords

HEPATITIS B SURFACE ANTIGEN;

ACCURACY; ARCHITECH HBSAG QUALITATIVE ASSAY; ARCHITECH HBSAG QUALITATIVE CONFIRMATORY ASSAY; ARTICLE; CONTROLLED STUDY; FALSE NEGATIVE RESULT; HEPATITIS B; HUMAN; IMMUNOASSAY; PRIORITY JOURNAL; RISK ASSESSMENT; SCREENING; SENSITIVITY AND SPECIFICITY; SEROCONVERSION;

BLOOD; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HUMANS; MASS SCREENING; SENSITIVITY AND SPECIFICITY; VIROLOGY;

EID: 79960371038     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2011.03.022     Document Type: Article

References (20)

1. Acar A., Kemahli S., Altunay H., Kosan E., Oncul O., Gorenek L., Cavuslu S. The significance of repeat testing in Turkish blood donors screened with HBV, HCV and HIV immunoassays and the importance of S/CO ratios in the interpretation of HCV/HIV screening test results and as a determinant for further confirmatory testing. Transfus. Med. 2010, 20:152-159.
2. Ch'ng S.L., How V.J., Soon K.F., Tan H.T. Dissociation of hepatitis B surface antigen (HBsAg) from immobilised anti-HBsAg antibody in a two site immunoradiometric assay: its relevance to hook effect and recycled assay. J. Immunoassay. 1987, 8:237-245.
3. Chan H.L., Wong V.W., Tse A.M., Tse C.H., Chim A.M., Chan H.Y., Wong G.L., Sung J.J. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin. Gastroenterol. Hepatol. 2007, 5:1462-1468.
4. Deguchi M., Yamashita N., Kagita M., Asari S., Iwatani Y., Tsuchida T., Iinuma K., Mushahwar I.K. Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay. J. Virol. Methods 2004, 115:217-222.
5. Fernando S.A., Wilson G.S. Studies of the 'hook' effect in the one-step sandwich immunoassay. J. Immunol. Methods 1992, 151:47-66.
6. Frieze T.W., Mong D.P., Koops M.K. "Hook effect" in prolactinomas: case report and review of literature. Endocr. Pract. 2002, 8:296-303.
7. Gerlich W.H., Kann M. Hepatitis B. Microbiology and microbial infections 1998, 745-773. Topley & Wilson, Arnold, London.
8. Hoofnagle A.N., Wener M.H. The fundamental flaws of immunoassays and potential solutions using tandem mass spectrometry. J. Immunol. Methods 2009, 347:3-11.
9. Jonas G., Pelzer C., Beckert C., Hausmann M., Kapprell H.P. Performance characteristics of the ARCHITECT anti-HCV assay. J. Clin. Virol. 2005, 34:97-103.
10. Kohmoto M., Enomoto M., Tamori A., Habu D., Takeda T., Kawada N., Sakaguchi H., Seki S., Shiomi S., Nishiguchi S. Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers. J. Med. Virol. 2005, 75:235-239.
11. La'ulu S.L., Roberts W.L. The analytic sensitivity and mutant detection capability of six hepatitis B surface antigen assays. Am. J. Clin. Pathol. 2006, 125:748-751.
12. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepat. 2004, 11:97-107.
13. Liu Y.S., Green A. A monoclonal-antibody enzyme immunoassay for detection of hepatitis B surface antigen with use of a biotin-avidin system. Clin. Chem. 1985, 31:202-205.
14. Louisirirotchanakul S., Khupulsup K., Akraekthalin S., Chan K.P., Saw S., Aw T.C., Cho D.H., Shin M.G., Lim J. Comparison of the technical and clinical performance of the Elecsys HBsAg II assay with the Architect, AxSym, and Advia Centaur HBsAg screening assays. J. Med. Virol. 2010, 82:755-762.
15. Manesis E.K., Schina M., Le G.F., Agelopoulou O., Papaioannou C., Kalligeros C., Arseniou V., Manolakopoulos S., Hadziyannis E.S., Gault E., Koskinas J., Papatheodoridis G., Archimandritis A.J. Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring. Antivir. Ther. 2007, 12:381-388.
16. Muhlbacher A., Weber B., Burgisser P., Eiras A., Cabrera J., Louisirirotchanakul S., Tiller F.W., Kim H.S., Helden J., Bossi V., Echevarria J.M. Multicenter study of a new fully automated HBsAg screening assay with enhanced sensitivity for the detection of HBV mutants. Med. Microbiol. Immunol. 2008, 197:55-64.
17. Nick S., Scheiblauer H. Sensitivities of CE-marked HIV, HCV, and HBsAg assays. J. Med. Virol. 2007, 79:S49-S64.
18. Palomaki P. Simultaneous use of poly- and monoclonal antibodies as enzyme tracers in a one-step enzyme immunoassay for the detection of hepatitis B surface antigen. J. Immunol. Methods 1991, 145:55-63.
19. Wursthorn K., Lutgehetmann M., Dandri M., Volz T., Buggisch P., Zollner B., Longerich T., Schirmacher P., Metzler F., Zankel M., Fischer C., Currie G., Brosgart C., Petersen J. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006, 44:675-684.
20. Zoulim F., Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy. J. Hepatol. 2008, 48(Suppl 1):S2-S19.